Genetic Engineering & Biotechnology News

DEC 2018

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: https://gen.epubxp.com/i/1052771

Contents of this Issue

Navigation

Page 6 of 57

GENengnews.com | Genetic Engineering & Biotechnology News | DECEMBER 2018 | 5 GENetic Engineering & Biotechnology News Scoop the You can read the full article online: GENengnews.com Top 10 Asia Biopharma Clusters 2018 Chinese Economy, Overseas Investment Scrutiny Challenge the East's Most Promising Regions This year's Asian biopharma cluster list includes all eight countries ranked in previous lists, including last year's list, with two new nations added to round out the ranking into a "Top 10"—same as GEN's U.S. cluster list and European cluster list. Countries are ranked on the following five criteria: Public R&D spending—Figures for most large nations appear in the Organization for Economic Co- operation and Development (OECD)'s most recent edition of its semiannual Main Science and Technology Indicators, last updated in July 2018. For nations not included in OECD data, typically smaller countries, GEN cited figures published by UNESCO Institute for Statistics on its website, which has been enhanced this year for easier country-to-country comparisons based on purchasing power parity dollars (PPP$). Patents—Based on the number of "biotechnology" and "pharmaceutical" patents as of May 19 that list at least one inventor from that nation in the World Intellectual Property Organization (WIPO) PATENT- SCOPE database, consisting of some 72 million patent documents, including 3.4 million international patent applications published through the Patent Coopera- tion Treaty (PCT) of 1970, under which applicants can simultaneously seek protection for their inventions in 148 countries. Initial public offerings—Given more robust activity compared with past years, countries were measured on 2018 IPO activity, based on figures from a combina- tion of publicly available data sources and company announcements. Number of companies—Combines figures furnished by the countries themselves on their own websites, in publicly available reports or public announcements, or in press articles when written by or directly attributed to an industry source. Jobs—Based on various sources, including industry groups, regional life sciences campuses, public and/ or private economic development groups, and press articles when written by or directly attributed to an industry source. Another source for some nations was the International Federation of Pharmaceutical Manu- facturers & Associations (IFPMA), which compiles an annual yearbook that includes employment numbers. Because of differences in criteria, such as inclusion of medical device or hospital patient-care positions, GEN found widespread discrepancies in job figures of several nations. 1 Only in patents does China lag, placing fourth (8447 list- ing at least one Chinese inventor, according to WIPO). The nation leads Asia in R&D ($451.201 billion in 2016, accord- ing to OECD), number of companies (about 7500), jobs (estimates over the past three years have ranged from 2,301,534 [IFPMA] to 2,882,903 [JLL])—and especially IPOs ($5.69 billion raised or planned by 18 companies). China 2 Japan leads the continent in patents (14,414 listing at least one Japanese inventor; WIPO), as well as a œrm number-two in R&D ($168.645 billion in 2016, according to OECD). Japan remains second in jobs (estimated between 210,000 and 878,000) but is third in companies (1100+, including 591 biotechs as of 2015; Japan Bioindustry Association), and third in IPOs (six companies raising a total $162.54 million). Japan 3 The "Land of the Morning Calm" enjoys strong showings in four of the œve measures. South Korea is second in patents (8479 listing at least one South Korean inventor; WIPO) and IPOs (10 companies). The nation places third in R&D ($79.354 billion in 2016; OECD) and in jobs (760,000), but sixth in number of companies (737; Korea Pharmaceutical and Bio-Pharma Manufacturers Association). South Korea 4 India is second in companies (4000+ pharmas, which also lists "about 800" biotechs). The nation is second in patents (8530 listing at least one Indian inventor; WIPO) and in jobs (587,468; IFPMA) but remains fourth in R&D ($50.269 billion in 2015, according to UNESCO œgures cited by the National Science Foundation) and œfth in IPOs (œfth with seven companies totaling $52.25 million). India 5 The "island continent" has climbed to fourth in number of companies (with 876, according to AusBiotech). It is œfth in patents (6556 listing at least one Australian inventor; WIPO) and in jobs (69,108, also according to AusBiotech), and it is sixth in R&D (A$31.179 billion [$22.153 billion] in 2015–16) and in IPOs (œve companies raising a combined A$51.4 mil- lion [$36.7 million]). Australia 6 Taiwan's strengths include R&D (œfth with $35.757 billion in 2016, according to OECD) and number of companies (œfth with 845). Taiwan œnishes seventh in both jobs (38,719 of 2016, according to MOEA) and IPOs ($35 million from the U.S. IPO of Taiwan Liposome), and eighth in patents (853 listing at least one Taiwanese inventor; WIPO). Taiwan 7 Singapore rose to œfth in IPOs, and sixth in patents (2032 listing at least one Singaporean inventor, according to WIPO) and seventh in R&D ($10.104 billion, according to UNESCO). The nation ranked eighth in jobs ("around 6900," according to the Singapore Economic Development Board) and tenth in companies with 100, including some 30 biopharma giants. Singapore 8 Malaysia is seventh in jobs (31,000), and companies. The nation remains eighth in both R&D ($9.728 billion accord- ing to UNESCO) and patents (ninth with 357 listing at least one Malaysian inventor, according to WIPO). Malaysia has not seen a biotech IPO since Bioalpha Holdings raised $5 million in 2015. Malaysia 9 Thailand places seventh in jobs (with estimates rang- ing from 2400 [Thailand Board of Investment] to 48,000 [IFPMA]). The nation is eighth in companies with "approxi- mately 200" as of 2016, according to the investment board. However, Thailand placed ninth in R&D ($5.147 billion, according to UNESCO) and 10th in patents (155 listing at least one Thai investor; WIPO). Thailand 10 Indonesia is 11th in R&D funding ($2.13 billion, according to UNESCO) and 12th in patents (38 listing at least one Indonesian inventor; WIPO). IFPMA lists the nation as having 64,059 pharma jobs, which would place the nation sixth. However, Indonesia ranks lower in companies (ninth with 182 domestic and state-owned companies, 24 multination- als), and had no biopharma IPOs this year. Indonesia Alex Philippidis

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - DEC 2018